Warning: mail() has been disabled for security reasons in /home/markrref/public_html/usmarketbuzz.com/wp-content/mu-plugins/bps-mu-tools.php on line 110

Warning: Cannot modify header information - headers already sent by (output started at /home/markrref/public_html/usmarketbuzz.com/wp-content/mu-plugins/bps-mu-tools.php:110) in /home/markrref/public_html/usmarketbuzz.com/wp-content/plugins/bigcontact/BigContact.php on line 43
McGraw-Hill Set to Record Best Year Since 2007 | US Market Buzz
Connect with us

Business

McGraw-Hill Set to Record Best Year Since 2007

Published

on

Northern, WI 02/15/2013 (usmarketbuzz) – McGraw-Hill Cos.(NYSE:MHP) is set to achieve its best financial year since 2007 as more and more corporate bonds are being issued. The company has been accused by the U.S. of disinformation about the risks that are involved in mortgage bonds that are reported as sub-prime. This had let to the credit crisis in the U.S.

The income for the company in major areas has scaled up to $970.8 million in the year 2012. Sales of its bonds recorded a high figure to the tune of $3.96 trillion.

Ed Atorino, an analyst said, “Bonds are being issued on a large scale. S&P’s a cash machine.”

In 2012, the Federal Reserve had to keep the interests rates at a low value in order to upscale the economy again. As corporate issuers of bonds hastened to book profits at low values, the company benefited a lot.

The U.S. Justice Department has alleged that S&P, in its efforts to get business from premier Wall Street banks, has given higher-than-actual ratings on mortgage- backed securities and collateralize debt obligations.

Analysts have predicted that McGraw-Hill is poised to report around $1.61 billion worth of sales for three months till 31st December.

McGraw-Hill will be selling its educational arm for $2.5 billion. This leaves the ratings and financial software business to be focused on.

The company has however refused to comment on its performance.

Yields on all types of corporate debts have reached a very low figure of 3.24% by the end of December. More bonds have been issued benefiting the credit raters. Profit increased by 66% in the fourth quarter as compared to the same period in the previous year. The net income also showed an increase.

The Securities and Exchange Commission has given McGraw-Hill the designation of a Nationally Recognized Statistical Rating Organization. S&P has ratings on varied debts, which can be utilized by investors to meet regulatory requirements.

The complaint filed against McGraw-Hill reports executives dismissing all relevant, ignoring warnings from analysts and taking various measures to satisfy bond issuers.

In the complaint, fees charged for grading a residential mortgage-backed security reached $150,000 and that for rating a collateralize-debt obligation, reached $750,000.

Speaking on the case filed against McGraw-Hill, a senior equity analyst said, “This issue is going to stay here. And frankly, it’s more likely going to get worse because we don’t know how many new additional lawsuits are going to be filed going forward.”

McGraw-Hill Cos.(NYSE:MHP) shares were down by 0.18% and currently trading at $44.78.

Continue Reading

Business

Top 3 Gainers: Zynga (NASDAQ:ZNGA), Eros International (NYSE:EROS), Borqs Technologies’ (BRQS)

Published

on

By

Zynga (NASDAQ:ZNGA) is up 2.5% after Benchmark reiterated its Buy rating in a look-ahead at Q2 earnings. The firm’s expecting a beat and solid guidance for Q3, and it’s raising its guidance for the fiscal year.

Tailwinds from the pandemic won’t dissipate easily, Benchmark suggests, and the videogame maker’s acquisition of Peak (and with it new “forever franchises” in Toon Blast and Toy Blast) will drive audience, bookings, margins and free cash flow, it says. The firm has an $11 price target, now implying 14% upside.

Eros International (NYSE:EROS) is up 5.8% today, making up the last week’s lost ground, after news that its streaming service Eros Now is partnering with Sony India (SNE +2.3%).

That will mean Eros Now’s app is pre-installed on selected Sony smart televisions in India, along with availability on a large base of existing models (Bravia E series and newer).

The country over the past year has seen a 25% growth in demand for smart TVs, fueled by overall industry growth of 15%, to a record 15M units/year.

Borqs Technologies’ (BRQS) personal safety tracker sees strong market with increased orders from the electronics retail chain in the US.

The boost in product demand comes ahead coronavirus pandemic that provides company to expect delivery of 250K units this year. It reflects over 3x the volume delivered in 2019, the year of its launch.

Borqs’ mobile personal safety devices designed particularly for senior citizens come with panic button, location tracking, and fall detection.

Continue Reading

Biotech

Biotech movers: Pfizer Inc. (PFE), Celgene Corporation (CELG)

Published

on

Pfizer Inc. (PFE) said on Thursday it received a request for documents as part of a U.S. investigation related to quality issues involving the manufacture of auto-injectors at its Meridian Medical Technologies site.

Pfizer, in a regulatory filing, said it would be producing records in response to the civil investigative demand from the U.S. Attorney’s office for the Southern District of New York.

Why ASDN Could Massively Outperform PFE in 2019

Meridian, a unit of Pfizer that manufactures EpiPen injectors used to deliver an emergency allergy antidote, has been hit by a series of manufacturing problems in recent years. Mylan NV, which markets EpiPens, has recalled tens of thousands of the devices after complaints that some had failed to activate.

Bristol-Myers Squibb has been meeting with shareholders in Boston and New York over the last two weeks to try to salvage its $74 billion purchase of cancer drugmaker Celgene Corporation (CELG), the biggest acquisition announced so far this year.

Why Investors Are Calling ASDN the CELG of the Sky!

The deal, announced in January, was hard sell to Bristol shareholders from the start. The acquisition adds about $32 billion in fresh debt to Bristol’s balance sheet while assuming $20 billion in Celgene’s debt, the companies said at the time. After factoring in debt, the acquisition was the largest health-care deal on record, according to data compiled by Refinitiv.

Now, hedge funds Wellington Management and Starboard Value say the deal doesn’t sit well with them. Bristol has sent executives to New York to meet with institutional investors several times over the last two weeks and met with investors in Boston on Wednesday and Thursday, according to a person who briefed on the meetings.

Bristol-Myers declined to comment.

Continue Reading

Biotech

Big Losers: Corbus Pharmaceuticals Holdings, Inc. (CRBP), Petróleo Brasileiro S.A. – Petrobras (PBR)

Published

on

Corbus Pharmaceuticals Holdings, Inc. (CRBP)’s shares slumped as much as 16% to $6.94 on huge volume. The stock has been showing intense sell off suddenly after a bearish article on seekingalph.com by Alpha Exposure.

The article stated that Corbus has ties to investors convicted of or alleged to have committed securities fraud. We believe lenabasum has failed its major trials in SSc and CF. Lenabasum was also denied Breakthrough Therapy Designation in SSc. We believe lenabasum will fail in its pivotal SSc and Phase 2b CF trials. We are short Corbus with a price target of $0.50.

Wow the future of Autonomous flight is finally here with the launch of ASDN passenger drone Elroy

Petróleo Brasileiro S.A. – Petrobras (PBR) is expanding its ambitious divestment program and has “bold” plans for sales, the Brazilian state-run oil company’s chief executive said after the firm posted its first annual profit in five years.

On a conference call with analysts to discuss fourth-quarter results, CEO Roberto Castello Branco said selling non-core assets will be key to deleveraging.

Petrobras, as the company is known, can reduce its ratio of net debt to earnings before interest, taxes, depreciation and amortization, or EBITDA, to 1.5 or even to 1, he added.

The University of Chicago-educated CEO, who took the reins in early January, has long been vocal about the need to slim down the sprawling firm and focus on core activities such as exploration and production. Thursday’s comments were some of his most assertive on the matter.

Why Investors Are Calling ASDN the TPC of the Sky!

Continue Reading
Advertisement

Trending